Table 3.

Cotinine-confirmed 7-day point prevalence abstinence logistic regression results, summary of treatment comparisons [Odds Ratio (95% Confidence Interval)]

Week	Pooled Effects		Pair Wise Treatment Comparisons
	Bupropion SR (n = 73)	CM (n = 66)	Bupropion SR + Non-CM vs. Placebo + Non-CM	Placebo + CM vs. Placebo + Non-CM	Bupropion SR + CM vs. Placebo + Non-CM	Bupropion SR + CM vs. Bupropion SR + Non-CM	Bupropion SR + CM vs. Placebo + CM	Bupropion SR + Non-CM vs. Placebo + CM
3†	3.7** (1.4 – 10.0)	2.0 (0.8 – 4.9)	2.3 (0.6 – 9.9)	1.1 (0.2 – 6.0)	5.9** (1.5 – 23.0)	2.5* (0.9 – 7.3)	5.3** (1.3 – 20.7)	2.1 (0.5 – 8.9)
4	2.5** (1.0 – 6.2)	1.8 (0.8 – 4.2)	1.1 (0.3 – 4.0)	0.6 (0.1 – 2.9)	3.3** (1.0 – 10.5)	3.0** (1.0 – 9.1)	5.3** (1.3 – 20.7)	1.7 (0.4 – 7.6)
5	2.6* (0.9 – 7.1)	2.0 (0.8 – 5.2)	1.6 (0.3 – 7.1)	1.1 (0.2 – 6.0)	4.1** (1.0 – 16.3)	2.6 (0.8 – 8.5)	3.7* (0.9 – 14.7)	1.4 (0.3 – 6.4)
6 (End of Treatment)	2.0 (0.7 – 5.6)	2.5* (0.9 – 7.1)	0.9 (0.2 – 4.7)	1.1 (0.2 – 6.0)	3.6* (0.9 – 14.4)	4.1** (1.0 – 16.3)	3.2 (0.8 – 13.0)	0.8 (0.1 – 4.2)
12 (Follow-Up)	2.6 (0.5 –13.6)	1.0 (0.2 – 4.2)	0.9 (0.1 – 6.7)	0.2§ (0.6 – 3.8)	1.8 (0.3 – 10.7)	2.1 (0.4 – 12.0)	10.5*§ (0.8 – 23.4)	5.3§ (0.2–13.9)

^§Calculated using Modified Median Unbiased Estimator of Odds Ratio and Bootstrapped 95% Confidence Interval (Parzen et al., 2002) due to cells with count zero

^†following initial two-week grace period

^**p < 0.05

^*p < 0.10